Jabbour, Elias

International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data

Arber, D. A., Orazi, A., Hasserjian, R. P., Borowitz, M. J., Calvo, K. R., Kvasnicka, H.-M., Wang, S. A., Bagg, A., Barbui, T., Branford, S., et al. (2022) · Blood

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 2,945

The distribution of T‐cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia

Williams, P., Basu, S., Garcia‐Manero, G., Hourigan, C. S., Oetjen, K. A., Cortes, J. E., Ravandi, F., Jabbour, E. J., Al‐Hamal, Z., Konopleva, M., et al. (2019) · Cancer

Acute Myeloid Leukemia ResearchCancer Immunotherapy and Biomarkers

Cited by 330

FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions

Antar, A. I., Otrock, Z. K., Jabbour, E., Mohty, M., & Bazarbachi, A. (2020) · Leukemia

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 243

Dasatinib

Kantarjian, H., Jabbour, E., Grimley, J., & Kirkpatrick, P. (2006) · Nature Reviews Drug Discovery

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 149

Long‐term follow‐up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic‐phase chronic myeloid leukemia

Naqvi, K., Jabbour, E., Skinner, J., Anderson, K., Dellasala, S., Yilmaz, M., Ferrajoli, A., Bose, P., Thompson, P., Alvarado, Y., et al. (2020) · Cancer

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 135

Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes

Montalban-Bravo, G., Kanagal-Shamanna, R., Benton, C. B., Class, C. A., Chien, K. S., Sasaki, K., Naqvi, K., Alvarado, Y., Kadia, T. M., Ravandi, F., et al. (2020) · Blood Advances

Acute Myeloid Leukemia ResearchCancer-related Molecular Pathways

Cited by 133

Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial

Short, N. J., Kantarjian, H. M., Loghavi, S., Huang, X., Qiao, W., Borthakur, G., Kadia, T. M., Daver, N., Ohanian, M., Dinardo, C. D., et al. (2019) · The Lancet Haematology

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 120

Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis

Boddu, P., Kantarjian, H. M., Garcia-Manero, G., Ravandi, F., Verstovsek, S., Jabbour, E., Borthakur, G., Konopleva, M., Bhalla, K. N., Daver, N., et al. (2017) · Blood Advances

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 112

Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options

Jabbour, E. J., Cortes, J. E., & Kantarjian, H. M. (2013) · Clinical Lymphoma Myeloma and Leukemia

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 105

Phase 2, randomized, double‐blind study of pracinostat in combination with azacitidine in patients with untreated, higher‐risk myelodysplastic syndromes

Garcia‐Manero, G., Montalban‐Bravo, G., Berdeja, J. G., Abaza, Y., Jabbour, E., Essell, J., Lyons, R. M., Ravandi, F., Maris, M., Heller, B., et al. (2017) · Cancer

Acute Myeloid Leukemia ResearchHistone Deacetylase Inhibitors Research

Cited by 104

Impact of the variant allele frequency of ASXL1 , DNMT3A , JAK2 , TET2 , TP53 , and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia

Sasaki, K., Kanagal‐Shamanna, R., Montalban‐Bravo, G., Assi, R., Jabbour, E., Ravandi, F., Kadia, T., Pierce, S., Takahashi, K., Nogueras Gonzalez, G., et al. (2020) · Cancer

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 101

Chronic Myeloid Leukemia: Mechanisms of Resistance and Treatment

Jabbour, E., Parikh, S. A., Kantarjian, H., & Cortes, J. (2011) · Hematology/Oncology Clinics of North America

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 68

Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia

Bidikian, A., Kantarjian, H., Jabbour, E., Short, N. J., Patel, K., Ravandi, F., Sasaki, K., & Issa, G. C. (2022) · Blood Cancer Journal

Chronic Myeloid Leukemia TreatmentsAcute Myeloid Leukemia Research

Cited by 55

Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL

Zhao, Y., Short, N. J., Kantarjian, H. M., Chang, T.-C., Ghate, P. S., Qu, C., Macaron, W., Jain, N., Thakral, B., Phillips, A. H., et al. (2023) · Blood

Acute Lymphoblastic Leukemia researchCAR-T cell therapy research

Cited by 41

Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL

Zhao, Y., Short, N. J., Kantarjian, H. M., Chang, T.-C., Ghate, P. S., Qu, C., Macaron, W., Jain, N., Thakral, B., Phillips, A. H., et al. (2024) · Blood

Acute Lymphoblastic Leukemia researchCAR-T cell therapy research

Cited by 41

Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical Trial

Jabbour, E., Oehler, V. G., Koller, P. B., Jamy, O., Lomaia, E., Hunter, A. M., Uspenskaya, O., Samarina, S., Mukherjee, S., Cortes, J. E., et al. (2025) · JAMA Oncology

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 33

Chronic myeloid leukemia without major molecular response after 2 years of treatment with tyrosine kinase inhibitor

Bidikian, A., Jabbour, E., Issa, G. C., Short, N. J., Sasaki, K., & Kantarjian, H. (2023) · American Journal of Hematology

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 32

Low-Dose Dasatinib (50 mg Daily) Frontline Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: 5-Year Follow-Up Results

Gener-Ricos, G., Haddad, F. G., Sasaki, K., Issa, G. C., Skinner, J., Masarova, L., Borthakur, G., Alvarado, Y., Garcia-Manero, G., Jabbour, E., et al. (2023) · Clinical Lymphoma Myeloma and Leukemia

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 30

The outcomes of patients with chronic myeloid leukemia treated with third‐line BCR::ABL1 tyrosine kinase inhibitors

Jabbour, E. J., Sasaki, K., Haddad, F. G., Issa, G. C., Garcia‐Manero, G., Kadia, T. M., Jain, N., Yilmaz, M., DiNardo, C. D., Patel, K. P., et al. (2023) · American Journal of Hematology

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 22

Olverembatinib in chronic myeloid leukemia—Review of historical development, current status, and future research

Kantarjian, H., Zhai, Y., Oehler, V. G., Jamy, O., Koller, P. B., Haddad, F. G., Sasaki, K., & Jabbour, E. J. (2025) · Cancer

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 10

The presence of additional cytogenetic abnormalities ( ACAs ) or Philadelphia chromosome variants do not adversely affect the achievement of treatment‐free remission in chronic myeloid leukemia

Haddad, F. G., Sasaki, K., Issa, G. C., Jabbour, E., & Kantarjian, H. (2024) · American Journal of Hematology

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 4